MedPath

Neurotech International's NTI164 Shows Promise in Pediatric Neurological Disorders

• Neurotech International is progressing with trials of NTI164, a drug targeting pediatric neurological disorders, showing potential in improving neural network function. • The drug aims to modulate neuroinflammation and enhance neuroprotection, addressing critical unmet needs in conditions like Autism Spectrum Disorder and Cerebral Palsy. • Clinical trials are underway to evaluate NTI164's efficacy in improving cognitive and motor functions, with initial data suggesting positive trends in treated patients.

Neurotech International is advancing clinical trials of NTI164, a novel drug aimed at treating pediatric neurological disorders. The trials focus on evaluating NTI164's ability to modulate neuroinflammation and enhance neuroprotection in conditions such as Autism Spectrum Disorder (ASD) and Cerebral Palsy.

Mechanism of Action

NTI164 is designed to improve neural network function by targeting key inflammatory pathways implicated in neurological disorders. Preclinical studies have demonstrated its potential in reducing neuroinflammation and promoting neuronal survival. The drug's mechanism involves modulating the activity of microglia and astrocytes, which play critical roles in the inflammatory response within the central nervous system.

Clinical Trial Progress

Clinical trials are currently underway to assess the efficacy and safety of NTI164 in pediatric patients. Initial data from these trials suggest positive trends in cognitive and motor function improvements among treated patients. These improvements are being evaluated through standardized assessments and neurophysiological measures.

Potential Impact

If successful, NTI164 could represent a significant advancement in the treatment of pediatric neurological disorders, addressing critical unmet needs in improving the quality of life for affected children and their families. Further data from ongoing trials are expected to provide more comprehensive insights into the drug's therapeutic potential.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Fast-Tracks NeuroVive's Traumatic Brain Injury Drug

The FDA has granted Fast Track designation to NeuroVive's drug, NeuroSTAT, aimed at treating moderate to severe traumatic brain injury (TBI). This status accelerates the drug's development and review process, offering more frequent FDA interactions and feedback. NeuroSTAT works by protecting mitochondria, aiming to prevent secondary brain damage post-TBI, with hopes of improving survival, quality of life, and neurological function. Early trials have shown promising results, including a 35% decrease in brain injury volume in experimental models.

Clearmind Medicine's CMND-100 Receives IRB Approval for AUD Clinical Trial at Yale

Clearmind Medicine received IRB approval for its Phase I/IIa clinical trial of CMND-100, a novel therapeutic targeting alcohol use disorder (AUD).
The trial, to be conducted at Yale School of Medicine, will assess the safety, tolerability, and efficacy of CMND-100 in reducing alcohol cravings.

Ignite Biomedical's AI-Driven TNFi Treatment Response Predictor Achieves Analytical Validation

Ignite Biomedical's Tumor Necrosis Factor-alpha Inhibitor (TNFi) Treatment Response Predictor (TRP) has achieved successful analytical validation, marking a key milestone in precision medicine.
The TNFi TRP utilizes RNA biomarkers identified through AI to predict patient response to TNF-alpha inhibitors, potentially transforming IBD patient care.

Neurotech Receives Approval to Commence Human Pharmacokinetic Study of NTI164

Neurotech has received ethics approval to begin a human pharmacokinetic study of its drug NTI164 in Adelaide.
NTI164, an oral cannabinoid drug, is being developed for neurological disorders involving neuroinflammation.

Neurotech International Advances NTI164 Drug Trials with Ethics Approval for Pharmacokinetic Study

Neurotech International has secured ethics approval to commence a pharmacokinetic study of NTI164 in healthy adults, a crucial step for regulatory compliance.
The study will provide essential data on the drug's metabolism and excretion, supporting its development for neurological disorders.

NIH's TrialGPT AI Algorithm Streamlines Clinical Trial Matching

The NIH has developed TrialGPT, an AI algorithm designed to efficiently match patients to relevant clinical trials listed on ClinicalTrials.gov.
TrialGPT demonstrated accuracy comparable to human clinicians in assessing eligibility criteria, while reducing screening time by 40% in a pilot study.

Intellia's CRISPR Therapy Nexiguran Ziclumeran Shows Promise in ATTR Amyloidosis Phase 1 Trial

Intellia's nexiguran ziclumeran (nex-z) demonstrates rapid and durable TTR reduction in ATTR amyloidosis patients, suggesting potential disease modification after a single dose.
In ATTR-CM patients, nex-z shows stabilization or improvement in cardiac markers at 12 months, including NT-proBNP, hs-Troponin T, and 6-minute walk test.

Intellia's CRISPR Therapy Nexiguran Ziclumeran Shows Promise in ATTR Amyloidosis Phase 1 Trial

Intellia's nexiguran ziclumeran (nex-z) demonstrates rapid and durable TTR reduction in ATTR amyloidosis patients, suggesting potential for significant clinical benefit.
The Phase 1 trial reveals stabilization or improvement in cardiac markers for ATTR-CM patients and neuropathy measures for ATTRv-PN patients after nex-z treatment.

Tivic Health Completes Enrollment in Vagus Nerve Stimulation Trial

Tivic Health has finished enrolling participants in a study evaluating its non-invasive vagus nerve stimulation (VNS) system.
The Feinstein Institute is conducting the trial to optimize device parameters like frequency and duration for influencing the autonomic nervous system.

Neuraptive's NTX-001 Receives FDA Breakthrough Therapy Designation for Peripheral Nerve Injury

NTX-001, a drug-device combination by Neuraptive Therapeutics, has received Breakthrough Therapy Designation from the FDA for treating peripheral nerve injuries requiring repair.
The designation was granted based on promising Phase 2 NEUROFUSE study results, potentially accelerating NTX-001's development and review process.

Reference News

[1]
Neurotech International Advances NTI164 Drug Trials - TipRanks.com
tipranks.com · Nov 24, 2024

Neurotech International Ltd. (AU:NTI) received ethics approval for a pharmacokinetic study of NTI164 in healthy adults, ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy